

1 July 2021

Steven Brandt appointed to Osprey Medical's Board of Directors

Minnesota, United States and Melbourne, Australia – 1 July 2021 – Osprey Medical, Inc. (ASX:OSP) (**Osprey or the Company**) is pleased to announce today the appointment of Steven Brandt to our Board of Directors. With over 35 years of experience in the healthcare field, Brandt is a welcome addition to the board and brings a wealth of expertise and knowledge to the role.

Notably, Steven holds over 10 years' experience as acting Vice President for Thoratec Corporation where he oversaw the rapid expansion of global revenue from \$104M to \$500M and the eventual acquisition by St. Jude Medical. Steven also held senior positions at CHF Solutions, St. Jude Medical and XRT Corporation (formerly Interventional Innovations). He has served on the board for Vascular Solutions, Inc. and currently sits on the board for Nuwellis, Inc. With his extensive experience in new therapy adoption in the cardiovascular space, Brandt's appointment to the board will provide new insight and expertise to further advance Osprey's expansion strategy.

Osprey CEO, Mike McCormick, said "Steven Brandt's extensive experience in new therapy adoption in the cardiovascular space represents a significant asset to the team. We are delighted to have Mr Brandt join as a Director and Osprey Medical will benefit immensely from his strategic input and diverse sector knowledge."

Steven Brandt spoke about his appointment as a Director of Osprey Medical, "I am delighted to join Osprey as the company has created a solution to prevent Contrast Induced Acute Kidney Injury events through its DyeVert technology. I'm excited to be a part of Osprey's mission to make angiography safer for Chronic Kidney Disease (CKD) patients."

This release dated 1, July 2021 has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.

– ENDS –

Contact details:

Osprey Medical

Doug Schoenberg
VP of Marketing
T: +1 (952) 955 8230
dschoenberg@ospreymed.com

Investor Relations

Prash Jitendran
Vesparum Capital
T: +61 3 8582 4800
ospreymed@vesparum.com

Media Relations

Ciara Byrne
Mana Communications
T: +61 41 3519 430
cbyrne@manacommunications.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.